COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision

March 15, 2019

Article

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.

According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the full comment letter.

Recent Videos

Tami John, MD

Tami John, MD

Tami John, MD

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Related Content

Tami John, MD

β-Thalassemia Gene Therapy in the Context of the Broader World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, emphasized the need to build community among patients with TDT.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial

Noah Stansfield

The IND clearance enables the company to start a first-in-human phase 1 clinical trial for the gene therapy.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

FDA Activity Recap: June 2025 Features New Platform Designation, IND Clearance, and More

FDA Activity Recap: June 2025 Features New Platform Designation, IND Clearance, and More

Noah Stansfield

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Related Content

Tami John, MD

β-Thalassemia Gene Therapy in the Context of the Broader World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, emphasized the need to build community among patients with TDT.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial

Rocket Snags IND Clearance for BAG3-DCM Gene Therapy Trial

Noah Stansfield

The IND clearance enables the company to start a first-in-human phase 1 clinical trial for the gene therapy.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

FDA Activity Recap: June 2025 Features New Platform Designation, IND Clearance, and More

FDA Activity Recap: June 2025 Features New Platform Designation, IND Clearance, and More

Noah Stansfield

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.